



US006291505B1

(12) **United States Patent**
Huebner et al.

(10) Patent No.: **US 6,291,505 B1**
(45) Date of Patent: **Sep. 18, 2001**

(54) **ESTROGEN RECEPTOR MODULATORS**

(75) Inventors: Verena D. Huebner, Benicia;
Xiaodong Lin, Walnut Creek, both of
CA (US); Ian James, Rowville (AU);
Liya Chen, East Brunswick, NJ (US);
Manoj Desai, Pleasant Hill, CA (US);
Beata Krywult, Armadale (AU);
Rajinder Singh, San Francisco; Liang
Wang, Lafayette, both of CA (US)

(73) Assignee: Chiron Corporation, Emeryville, CA
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/369,747

(22) Filed: Aug. 6, 1999

Related U.S. Application Data

(60) Provisional application No. 60/095,772, filed on Aug. 7,
1998.

(51) Int. Cl.⁷ A61K 31/415; A61P 19/10;
C07D 231/12

(52) U.S. Cl. 514/406; 548/377.1

(58) Field of Search 548/377.1; 514/406

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,112,108 9/1978 Nadelson .
4,229,204 10/1980 Howe .

FOREIGN PATENT DOCUMENTS

2441504 A1 8/1974 (DE) C07D/231/12
31 19727 A1 5/1981 (DE) .
41 26543 A1 2/1993 (DE) C07D/231/54
42 30 839 A1 3/1993 (DE) C08G/65/40
44 08 084 A1 3/1994 (DE) .
0 026 928 3/1980 (EP) .
0 442 448 A2 2/1991 (EP) C07D/207/327
0 623 603 A1 10/1993 (EP) .
2104932 8/1970 (FR) A61D/27/00
WO 96/25405 8/1996 (WO) .
WO 97/01551 1/1997 (WO) C07D/403/04
WO 00/75131 12/2000 (WO) .

OTHER PUBLICATIONS

Amme, Omar et al.; "Synthesis, binding affinities and
uterotrophic activity of some 2-substituted estradiol and
ring-A-fused pyrone derivatives", XP-002136351, *Eur J
Med Chem* 29:25-32 (1994).
Duncan, Dean C. et al.; "The Preparation of N-Carboalkoxy
pyrazoles and N-Phenylpyrazoles from C(α)-Dianions of
Carboalkoxyhydrazones and Phenylhydrazones", XP-002136350,
J. Heterocyclic Chem., 24:555 (1987).

Fink, Brian E. et al.; "Novel structural templates for estro-
gen-receptor ligands and prospects for combinatorial syn-
thesis of estrogens", XP-000905542, *Chemistry & Biology*,
6:205-219 (Apr. 1999).

Sun, Jun et al.; "Novel Ligands that Function as Selective
Estrogens or Antiestrogens for Estrogen Receptor- α or
Estrogen Receptor- β ", XP-000908867, *Endocrinology*, vol.
140, 2:800-804 (1999).

Wachter, Gerald A. et al.; "Tetrahydronaphthalenes: Influ-
ence of Heterocyclic Substituents on Inhibition of Ste-
roidogenic Enzymes P450 arom and P450 17",
XP-002099563, *J. Med. Chem.*, 39:834-841 (1996).

Meisenheimer et al.; "Uber Triaryl-isoxazole", *Chemische
Berichte*, (1921)3195-3206.

Krishna et al.; "Synthesis and Physiological Activity of
3-Hydrxy-Pheny-5-Aryl Isoxazoles", *Chemical Abstracts*,
(1973) 79(13):487.

Yamawaki et al.; "Synthesis and Biological Activity of the
Metabolites of [3,4-Bis(4-Methoxyphenyl)-5-Isoxazolyl]
Acetic Acid", *Chemical and Pharmaceutical Bulletin*,
(1988) 36(8):3142-3146.

Kim et al.; "Reactions of 5-Substituted 3-Alkyl- and
3-Aryl-Isoxazoles with Tetrasulfur Tetranitride Antimony
Pentachloride Complex (S₄N₄SbCl₅): Complete Regioselec-
tive Formation of 4-Substituted 3-Acyl- and 3-Aroyl-1,2,
5-Thiadiazoles and their Mechanism of Formation", *Jour-
nal of the Chemical Society*, (1998) 14:2175-2180.

Mohan et al.; "Search for Physiologically Active Com-
pounds. XIV Synthesis of some 3,5-Disubstituted Isox-
azoles and their Physiological Activity", *Chemical
Abstracts*, (1968) 69(11):4107.

Wrobel et al.; "Conversion of 1-(O-Nitroaryl) Alkyl
P-Tolysulfones into Isoxazoles", *Heterocycles*, (1995)
40(1):187-190.

Kasturi et al.; "Reaction of Spironaphthalenones with
Hydroxylamine Hydrochloride: Part IV¹", *Tetrahedron*,
(1995) 51(10):3051-3060.

Primary Examiner—Robert W. Ramsuer

(74) *Attorney, Agent, or Firm*—David P. Lentini; Robin
Teskin; Robert P. Blackburn

(57) **ABSTRACT**

Estrogen receptor-modulating pyrazole compounds are
described in addition to methods and compositions for
treating or preventing estrogen receptor-mediated disorders.
The compounds described have been found to have unex-
pected and surprising activity in modulating estrogen recep-
tor activity. Thus, the compounds of the present invention
have utility in preventing or treating estrogen receptor-
mediated disorders such as osteoporosis, breast and endome-
trial cancers, atherosclerosis, and Alzheimer's disease.

12 Claims, No Drawings